How Technology Has Helped Shape The Innovation Of Drug Dosage Forms And Support Patient-Centric Goals

Technological innovations are enabling high potency active pharmaceutical ingredients (HPAPIs) — traditionally found in most parenteral formulations — to be used in more OSD treatments, allowing the pharmaceutical industry to move away from a one-size-fits-all approach to drug development and towards treatments that are more tailored to patient populations. Delivering highly potent drug formulations via parenteral forms often requires administration in a clinical setting by healthcare professionals to ensure safety and compliance. However, delivering these drugs in OSD form via tablets or capsules is preferable for both patients and healthcare professionals, as they boost patient compliance and convenience while freeing up time for healthcare professionals.

However, delivering HPAPIs in OSD form requires developers to overcome significant challenges to solve the API release issues of highly potent formulations. When partnering with a CDMO to formulate and manufacture your HPAPI drug product, it is important to look for not only comprehensive technical capabilities but also experience and success at commercializing complex OSD formulations. Learn how delivering these drugs in OSD form via tablets or capsules can help boost patient compliance and consider the complex formulation challenges inherent to HPAPI development and manufacturing.